Recent studies have found that OCA shows potential value in the treatment of NAFLD, especially NASH ( However, in our current study, we only describe preliminary framework analyses of caffeine and EGCG in the context of NASH and do not further explore or verify the differential genes and pathways
GLP-1 receptor agonists slow gastrointestinal transit time
New JAMA Study Links Wegovy to NAION A JAMA study published on July 3, 2024, on the Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide found an increased risk of the condition in patients taking semaglutide compared to those taking non-GLP-1 RA medications
It is a medically monitored program
It is considered a metabolic drug rather than a stimulant and does not carry the same risk of addiction or dependence
However, Wegovy injections are formulated at a higher dose in order to be more effective as a weight loss medication